Great news for SA. They relied heavily on J&J and provide much knowledge about J&J's lower efficacy vs other vaccines. They've now joined most of the world in recommending 2 boosters after J&J.
Meanwhile the USA is still stuck on 1 booster only for JnJers.
And despite having been one of J&J's most vocal supporters, South Africa's health ministry is allowing heterologous boosting. That heterologous boosting works better than homologous boosting for J&J is now common knowledge.
In case we needed another reminder, a paper just came out last week (one I had analyzed as a preprint) showing J&J + 1xPfizer was much better than J&J + J&J, and similar to 2xPfizer, finally sciencedirect.com/science/articl…
And regarding CDC data that JnJers in the US got Omicron at lower frequency than RNA recipients: such data are uninterpretable without splitting the groups by history of COVID and boosters. AFAIK boosted/infected/unboosted/naive were all grouped together.
It's exceedingly unlikely that unboosted uninfected 1xJ&J can more effective than unboosted uninfected 2xRNA vs Omicron because all the evidence is their nAbs are far lower. I covered this earlier
And in the controlled setting of monkey studies, a J&J booster clearly produces lower anti-Omicron Abs than a RNA booster, when added to either a 1xJ&J or 2xRNA primary series.
Thus serology predicts J&J blocks Omicron infection worse than RNA per dose
Not to mention, as we knew, that JNJ x1 (Ad26 here) as an initial "vaccine" is far inferior in anti-Omicron antibodies to RNA x2 (BNT2x here), regardless of whether you boost with another RNA or a JNJ dose later.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Novavax beats Moderna, which (transiently) induces higher levels of neutralizing Abs. As I've said before, Abs are much more than neutralization. Ab effector functions do most of the clearing, and Novavax seems particularly good at that.
And this is in the 2-dose Phase 3 trials, before the 3rd "booster" dose that, in RNA vaccines but not Novavax, induces antibody (immunoglobulin) class-switching to the no-effector-function IgG4
I made this graphic to show how different vaccine types work (back in 2021).
We can just look at line 1 (protein vax like Novavax) and line 3 (RNA vax).
In protein vax, antigen-presenting cells take up the antigen to activate B cells and Thelper cells....
In RNA vax, your muscles cells take up RNA and translate it into antigen. This process tends to be a bit inflammatory (apparently that's inherent to RNA uptake) so some cells die and release proteins that are also taken up by antigen-presenting cells.
Basically Pelosi figured out Donilon was the one feeding Biden hopium-spiked poll results, and leaked it out.
Once it was proven that there really was bad info in the inner circle, that gave everyone else confidence in their own eyes. The emperor really was naked.
“Put Donilon on the phone,” Ms. Pelosi told the president, referring to Mike Donilon, the president’s longtime aide, according to people familiar with the exchange, which was reported earlier by CNN. “Show me what polls.”
Biden has COVID-19 again. He had first symptoms today, positive test today, and first Paxlovid dose today.
As the early Paxlovid will limit immunostimulation by virus, I predict he will suffer rebound again, unless he gets 10-day course, or he is given a strain-matched vaccine.
Biden's DO does not seem to follow the science. The rate of rebound is 26% if started within the first 2 days of symptoms or positive test.
Sure, FDA and CDC and Pfizer still claim it's less than 3% and no different than no-Paxlovid, but it fools nobody
I predicted his first rebound on immunological principles alone and on understanding Paxlovid mechanism of action. It was a real prediction, made before it happened, and sticking my neck out in public to make it.
I intuited that early start of Paxlovid blunts immunity, allowing viral rebound once drug ended. I thus predicted both Joe and Jill Biden's rebounds (before they occurred), as they started Pax on day of symptoms.
"The model identifies that earlier initiation and shorter treatment duration are key predictors of post-treatment rebound."
The model shows that early therapy reduces the number of infected cells secreting innate immune signals (IFNs) that then activate antibody production.
"If the virus is not eliminated by an early acquired response along with antiviral pressure, it rebounds to a peak level that is sometimes comparable to the initial peak."
We have seen this with many people, e.g. Fauci reported the rebound was worse than the initial infection